CA
NZ
UK
AU
IND
US
This substantial drop is primarily due to the prior year's impressive figures, which included a $175 million milestone from the Nuvaxovid vaccine's Biologics License Application approval. Despite this decline, Novavax exceeded analyst expectations, reporting an earnings per share (EPS) loss of $-0.32, which was …
Year-to-date, the company’s stock has decreased by 26.9%, despite a 6.9% recovery over the past month, indicating potential volatility. Market conditions and the broader sector’s performance could influence Nuvation Bio's future trajectory. Achieving this slightly better-than-expected EPS may temper investor concerns, suggesting a cautiously …
Lantheus Holdings, Inc. (NASDAQ: LNTH) reported strong financial results for the second quarter, achieving worldwide revenue of $388.2 million, reflecting a 2.7% increase compared to $378.0 million in the same quarter last year. This revenue figure exceeded the consensus estimates, following earlier reports where …
The missed expectation comes as the company continues to navigate complex clinical timelines, particularly as it prepares for the resubmission of its New Drug Application (NDA) for ZYNQUISTA in type 1 diabetes later this year. The company’s stock has risen 109.2% year-to-date, reflecting investor …
LifeStance Health Group, Inc. (NASDAQ: LFST) posted second-quarter revenue of $435.4 million, a significant 26% increase compared to $345.3 million in the same period last year. The company also announced a $100 million share repurchase program, replacing its previous repurchase plan. LifeStance exceeded analyst …
Ligand Pharmaceuticals reported a significant increase in royalty revenue for Q2 2026, reaching $48 million. This figure represents a strong 32% growth compared to the same quarter last year, driven primarily by higher earnings from key products like Travere Therapeutics’ Filspari and Pelthos Therapeutics’ …
MBX Biosciences, Inc. (NASDAQ: MBX) announced earnings per share (EPS) of $-0.78 for the quarter ending June 30, 2026, falling short of consensus expectations. While the result highlights ongoing financial pressures, the company continues to advance its clinical pipeline, positioning it for future growth …
Moderna's recent FDA approval for its COVID-19 vaccine represents a important achievement in regulatory support for the company. However, despite this win, market reactions have been tepid, with investors expressing hesitance about the durability of positive momentum. The approval underscores the vaccine's safety and …
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced a second-quarter loss of $-0.43, which falls short of the consensus estimate of $-0.39, raising caution among investors. The company revealed these financial results on August 6, 2026, alongside updates on its ongoing clinical trials. The reported …
Immunocore Holdings plc (NASDAQ: IMCR) posted second‑quarter net product revenue of $115.9 million, an 18% increase from $98.0 million a year earlier, while the loss for the period narrowed dramatically to $0.8 million, translating to a $‑0.02 earnings per share versus the $0.01 consensus …
Please wait processing your request...